Physician profile
David Michael Mcmahon
NPI 1457662249
$5,791.24
in general payments reported to CMS, 2019-2025
30 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $271 · 2021: $59.19 · 2022: $346 · 2023: $202 · 2024: $1,396 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.73 |
| Education | $226.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $884.43 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $564.29 | 2019-2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $548.51 | 2019-2025 | Rexulti |
| Lundbeck LLC | $467.74 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $462.26 | 2021-2025 | |
| Axsome Therapeutics, INC. | $407.84 | 2024-2025 | Auvelity |
| Indivior INC. | $350.43 | 2019-2025 | Sublocade |
| Ironshore Pharmaceuticals INC. | $342.39 | 2019-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $325.24 | 2021-2025 | Caplyta |
| Allergan, INC. | $212.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $149.59 | 2019-2025 | Spravato |
| Tris Pharma INC | $141.02 | 2019-2025 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $127.39 | 2019-2025 | Ingrezza |
| Collegium Pharmaceutical, INC. | $116.74 | 2025 | Jornay Pm |
| Brainsway USA INC | $100.00 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $91.16 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $72.40 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.13 | 2020-2025 | Trintellix |
| Shire North American Group INC | $65.68 | 2019 | |
| Corium, LLC | $43.71 | 2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $35.99 | 2019 | |
| Braeburn INC. | $34.40 | 2025 | Brixadi |
| Jazz Pharmaceuticals INC. | $30.89 | 2019-2020 | |
| Neos Therapeutics, LP | $28.86 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $26.92 | 2019-2025 | Relexxii |
| Vanda Pharmaceuticals INC. | $25.98 | 2019 | |
| Almatica Pharma LLC | $19.43 | 2025 | Loreev Xr |
| Noven Therapeutics, LLC | $17.16 | 2024 | Secuado, Xelstrym |
| Sage Therapeutics, LLC | $14.21 | 2025 | Zurzuvae |
| Bausch Health US, LLC | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mcmahon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.